“Would anyone else do any better” Well, I reckon Pfizer or GSK would have taken less than nearly two decades to either 1. Get this product licensed for use or 2. Write it off is ineffective and move on
Sharedealer - re your football analogy. RM is the Manager, not the goalkeeper. He has had nigh on 20 years to produce results and won nothing yet. You don’t last long in football management with his record
Fair enough observation, but it’s perfectly legitimate for someone to hold shares in this business because they are persuaded by the potential of the drug, whilst at the same time criticising the CEO because of the abject/avoidable failure of a trial conducted on his watch
B2HS2L - Don’t just focus on big pharma though. I mentioned a few months ago that like it or not, this business would be a perfect fit for Phillip Morris International. As part of their “smoke free future” mission, they are on the hunt for respiratory drug businesses. They bought Otitopic and Vectura in 2021. Any Inhaled therapeutics/research businesses will be in their crosshairs, and given Synairgens market value at the moment, PM could absorb this Company into their portfolio just by dipping into their tea fund money
Andyb4 and MrCosts make perfectly valid points in my view. This most recent interview with RM was disgraceful. Who is going to take responsibility for this badly designed trial? Well, no one as yet. It all seems to be business as usual. More trials, maybe veer back to COPD blah blah.
I can only hope that Polygon are making discreet approaches to players with big pharma experience before starting manoeuvres to oust this hapless CEO.
RM needs reminding that one of his principal responsibilities is to maximise returns for shareholders. At the moment he is only maximising returns for himself and other members of his team who contributed to this trial debacle.
PM also bought OtiTopic last summer - another respiratory drug Company. They are on the hunt to boost the credibility of their smoke free mission statement, and with a huge war chest. Synairgen must be in their cross hairs.
Guess we will find out soon one way or another
Any low volume of daily trades allows B of A to marshall the market but the bottom line is that they are accumulating
Bank of America now increased to 7.8%. Sold to reduce price per share and then buy at a cheaper rate. They ain’t going away